Posted by Michael Wonder on 09 Nov 2021
TGA grants provisional determination to AstraZeneca for COVID-19 preventative treatment, tixagevimab and cilgavimab (Evusheld)
9 November 2021 - On 4 November 2021, the TGA granted provisional determination to AstraZeneca in relation to the COVID-19 treatment tixagevimab and cilgavimab (Evusheld).
The granting of a provisional determination means that the TGA has made a decision that AstraZeneca is now eligible to apply for provisional registration for Evusheld in the Australian Register of Therapeutic Goods.
